Women’s Health Is Widening Faster Than Its Evidence Base 1 Oct 2026

Across the newsletters we read, the innovation events we attend and the conversations arriving in our inbox, women’s health has become one of the most consistently recurring subjects of the past year. That is a change worth noting in itself. What follows is not a market forecast. It is an account of what the traffic looks like from where we sit, and what we think it means for companies developing in this space.

The clearest pattern is a definitional one, and it has consequences that go well beyond terminology.

The category is being redrawn

Women’s health has historically been treated as a synonym for reproductive health: fertility, contraception, pregnancy and the care surrounding them. The working definition now in use across the events and discussions we see is considerably wider, taking in cardiovascular disease, autoimmune conditions, mental health, oncology, menopause, osteoporosis and healthy ageing.

The reasoning behind the expansion is sound. Women experience many conditions differently from men, in presentation, in progression and in response to treatment, and those differences have not consistently been reflected in trial design, diagnostic pathways or treatment development.

But redefining a category does not by itself produce the evidence needed to develop in it. A field that has just widened its scope by an order of magnitude has, for most of that new territory, the research base of the narrower field it replaced.

The shift: women’s health has been redefined from a therapeutic niche into a lens applied across most of medicine, and the evidence base has not yet caught up with the definition.

Where we see the gap sitting

The under-research of women’s health is well established and widely acknowledged. What we hear discussed less often is that the gap is not evenly spread, and this is an observation from our own vantage point rather than a finding we can point to a study for.

In the programmes and enquiries that reach us, reproductive and gynaecological health — while far from solved — tends to come with a genuine research tradition behind it. The newer territory does not. Where we most often see teams having to generate foundational evidence themselves is in the sex-specific picture for cardiovascular disease, for autoimmune conditions, for the presentation and treatment of mental illness, and for how conditions and treatments interact with the menopausal transition.

For a developer, that distinction is more useful than the headline claim about under-investment, because it determines how much of the groundwork a programme has to carry itself rather than draw on. It is worth establishing early, and specifically for your indication, rather than assuming the category-level narrative applies evenly across it.

Why AI matters most where the data is thinnest

Artificial intelligence is discussed in almost every women’s health forum we encounter, usually in general terms about pattern recognition and accelerated discovery. The more specific argument is the more interesting one.

AI’s contribution is largest precisely where the existing evidence base is weakest and most fragmented, because that is where conventional analysis has least to work with. Women’s health, having been systematically under-studied, is close to a best case for approaches that can surface signal in incomplete and heterogeneous data.

The qualification matters as much as the claim. A model trained on data that under-represents women will reproduce that under-representation, and do so with an appearance of authority. In a field defined by a historical data gap, the governance question is not an afterthought to the opportunity. It is part of it.

What investors appear to be asking for

On investment we would rather be straightforward than confident. The picture reaching us is genuinely mixed: sustained interest in the category alongside a more demanding posture on individual propositions. We are not in a position to call the direction of the funding cycle and would treat anyone who is with some caution.

What does come through consistently is a change in what is being asked for. The propositions attracting attention are those that pair a clearly defined clinical need with evidence of measurable improvement in outcomes, healthcare efficiency or quality of life. Scientific novelty alone is doing less work than it was.

For companies in this space, that favours anyone who has built health economic and real-world evidence thinking into development early, and disadvantages anyone treating it as a step to be taken after clinical proof of concept.

Menopause has become two conversations

The most striking change we have observed is that menopause is now discussed in two distinct registers at once: as a clinical field, and as a workplace and employment issue affecting retention, productivity and wellbeing.

These have different audiences, different evidence requirements and different buyers. A product addressing menopausal symptoms is assessed clinically. A programme addressing menopause in the workforce is bought by employers on quite different criteria. Companies moving between the two framings without recognising the difference tend to make arguments that persuade neither.

What we take from it

Women’s health is no longer a discrete therapeutic area. It has become a lens applied across most of medicine, and the practical consequence of that is an evidence burden rather than a market opportunity in isolation.

For developers the implication is fairly concrete. The widening of the category has opened genuine opportunity, and it has simultaneously raised what has to be demonstrated, because much of the new territory lacks the sex-specific evidence base that would otherwise be drawn on. Companies that plan for that from the outset, in trial design, in evidence generation strategy and in how they will demonstrate value to payers, will find the path considerably shorter than those that discover the gap at the point of assessment.

PharmaMedic Consultancy supports pharmaceutical and biotechnology companies with medical affairs, regulatory strategy and evidence generation, including in therapy areas where the existing evidence base is limited. If you are developing in women’s health and would like to discuss your evidence strategy, please contact us at hello@pharmamedic.co.